Search results
Results from the WOW.Com Content Network
Currently, if the hepatic adenoma is >5 cm, increasing in size, symptomatic lesions, has molecular markers associated with HCC transformation, rising level of liver tumor markers such as alpha fetoprotein, the patient is a male, or has a glycogen storage disorder, the adenoma is recommended to be surgically removed. [7]
FLC accounts for 1–10% of primary liver cancers. [24] It typically has a young age at presentation when compared to conventional HCC. Previously it was estimated to be 20–40 years, mean ages 27 years, [ 25 ] but when analysis is restricted to those patients who are confirmed with a molecular test to have FLC, the age range is 10-40 and mean ...
The L3 isoform is specific to malignant tumors and its detected presence can serve to identify patients whom need increased monitoring for the development of HCC in high risk populations (i.e. chronic hepatitis B and C and/or liver cirrhosis). AFP-L3% is now being considered as a tumor marker for the North American demographic.
A liver metastasis is a malignant tumor in the liver that has spread from another organ that is affected by cancer. The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein). Metastatic tumors in the liver are 20 times more common than primary liver ...
Barcelona Clinic Liver Cancer (BCLC) Staging System. The prognosis of HCC is affected by the staging of the tumor, the liver's function due to the effects of chronic liver disease and cirrhosis as well as the person's physical performance status. [48] A number of staging classifications for HCC are available.
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
Two areas in particular that are receiving attention as surrogate markers include circulating tumor cells (CTCs) [45] [46] and circulating miRNAs. [47] [48] Both these markers are associated with the number of tumor cells present in the blood, and as such, are hoped to provide a surrogate for tumor progression and metastasis. However ...
Liver cancer can be primary in which the cancer starts in the liver, or it can be liver metastasis, or secondary, in which the cancer spreads from elsewhere in the body to the liver. Liver metastasis is the more common of the two liver cancers. [3] Instances of liver cancer are increasing globally. [8] [9]